OCT 26, 2020 1:04 PM PDT

Investigating the Receptor Protein FPR1 in Brain Cancer

WRITTEN BY: Jasper Cantrell

Amongst the more common targets for cancer therapies are cell surface receptors. These receptors are proteins – usually involved in transmitting signals into the cell – and are key signal gateways. Therefore, blocking a single receptor could stop whole signal pathways in the cell and maybe even stop cancer in its tracks.

Researchers have identified a new receptor, formylpeptide receptor 1 (FPR1), that might be a good target for anti-cancer drugs. This receptor is part of a family of receptors involved in chemotaxis (a part of how cells move) for immune cells called leukocytes. Recent studies have found that FPR1, in particular, plays a pro-cancer role in many tumor types.

In a new study, a team out of the University of Bradford in the United Kingdom wanted to investigate if FPR1 played a role in colorectal cancer. Other studies have already linked it to brain, colon, and breast cancers, but there wasn’t any evidence of it playing a part in colorectal cancer. There is even evidence that it has a role in resistance and recurrence.

The team would analyze FPR1 expression in colorectal cancer in vitro and in vivo with several other cancer types used as controls to investigate their hypothesis. They would also test how a robust FPR1 inhibitor, developed by the same team in a previous study, would affect cancer cells in the same models.

They first investigated FPR1 levels in a variety of cancer cell lines in vitro. They found that colorectal cancer indeed had FPR1 levels similar to other studied cancers. They also saw an interesting correlation between FPR1 levels and ANXA (an activator of FPR1) levels in hypoxic/necrotic conditions in the brain cancer cell line both in vitro and in vivo.

After the interesting finding with the brain cancer cell line, the team decided to pivot to investigating FPR1’s role there. They tested the FPR1 inhibitor they had developed in a previous study, ICT12035 could prevent the FPR1 dependent cancer growth. They induced FPR1 using an activator molecule, fMLF, which increased cell invasion in the brain cancer cell line. The inhibitor's application effectively prevented this increase in cell invasion and could even suppress cancer cell growth in mouse models.

This study showed that FPR1 was indeed expressed in colorectal cancer as in other cancer types. After an interesting find in a brain cancer cell line, the team shifted their testing. Using the brain cancer cell line, they saw that the FPR1 inhibitor ICT12035 could suppress cancer growth both in vitro and in a mouse model. They also saw that hypoxic conditions, often found in tumors, have higher levels of FPR1, inferring the receptor may play a role in tumor formation or maintenance.

The study concludes, “Further investigation of ICT12035, or other FPR1 antagonists, can open opportunities for more efficient treatment for cancers, including glioma, in due course.”

Sources: Nature Scientific Reports, khanacademymedicine

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
SEP 06, 2020
Cancer
Focal HIFU ablation improves prostate cancer patients' quality of life
SEP 06, 2020
Focal HIFU ablation improves prostate cancer patients' quality of life
Research published in The Journal of Urology offers an alternative to invasive prostate cancer treatments like surg ...
SEP 18, 2020
Coronavirus
How Coronavirus Spread in the US and Europe
SEP 18, 2020
How Coronavirus Spread in the US and Europe
Researchers are beginning to examine how the world's response to the pandemic virus SARS-CoV-2 went wrong, and right ...
OCT 05, 2020
Cancer
Fighting mitochondrial terminal exhaustion
OCT 05, 2020
Fighting mitochondrial terminal exhaustion
New findings reported in Nature Immunology highlight how the tumor microenvironment attacks the mitochondria of T l ...
OCT 08, 2020
Immunology
Immuno Metabolic Complexity and Modulating Metabolites
OCT 08, 2020
Immuno Metabolic Complexity and Modulating Metabolites
Immunometabolism is a relatively new subspecialty of immunology as we’ve begun to unravel the complex metabolic re ...
OCT 09, 2020
Cancer
Cloud technology cuts improve efficiency for cancer nurses
OCT 09, 2020
Cloud technology cuts improve efficiency for cancer nurses
In a new study reported in Clinical Cancer Informatics, an American Society of Clinical Oncology journal, medical provid ...
OCT 23, 2020
Cancer
#BCSM helps physicians understand patients' needs outside the clinical setting
OCT 23, 2020
#BCSM helps physicians understand patients' needs outside the clinical setting
A new study from UCLA published in the Journal of Patient-Centered Research and Review suggests that social media can be ...
Loading Comments...